Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TLR2 | O60603 | 1/20 | 0.54 |
| ▸ | NSD2 | O96028 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MPI | P34949 | 1/20 | 0.54 |
| ▸ | GRK6 | P43250 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.54 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449698 | 0.88 | HDAC4 (0.73) | HDAC4HDAC6ALDH1A1MAPTKDM4E | |
| SCHEMBL29617026 | 0.84 | HDAC4 (0.64) | HDAC4HDAC6ALDH1A1MAPTKDM4E | |
| SCHEMBL669793 | 0.82 | HDAC4 (0.62) | HDAC4HDAC6ALDH1A1MAPTKDM4E | |
| SCHEMBL14052281 | 0.81 | HDAC4 (0.70) | HDAC4HDAC6ALDH1A1MAPTKDM4E | |
| SCHEMBL1828976 | 0.81 | HDAC4 (0.65) | HDAC4HDAC6ALDH1A1MAPTKDM4E | |
| SCHEMBL28427399 | 0.81 | HDAC4 (0.65) | HDAC4HDAC6ALDH1A1MAPTKDM4E | |
| SCHEMBL22618595 | 0.80 | ALDH1A1 (0.57) | HDAC4HDAC6ALDH1A1MAPTKDM4E | |
| SCHEMBL19287236 | 0.80 | HDAC4 (0.42) | HDAC4HDAC6ALDH1A1MAPTKDM4E | |
| SCHEMBL362159 | 0.79 | TSHR (0.63) | HDAC4HDAC6ALDH1A1MAPTKDM4E | |
| SCHEMBL3824966 | 0.79 | HDAC4 (0.63) | HDAC4HDAC6ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158677-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
| US-6465647-B1 | Oxygen, sulfur and nitrogen substituted cyclohexene and cyclohexane derivatives having retinoid-like biological activity | ALLERGAN, INC. | 2002-10-15 | — | — | US | disclosed |
| US-6465646-B1 | 1-alkoxy and 1-acyloxy substituted cyclohex-1-ene compounds and sulfur and 1-alkoxycarbonyl analogs having retinoid-like biological activity | ALLERGAN, INC. | 2002-10-15 | — | — | US | disclosed |
| US-6177588-B1 | HAVING RETINOID-LIKE, RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST-LIKE BIOACTIVITY; SIDE EFFECT REDUCTION; SKIN DISORDERS; ANTIPROLIFERATIVE AND -CARCINOGENIC AGENTS; MICROBIOCIDES; VISION DEFECTS; CARDIOVASCULAR DISORDERS | ALLERGAN SALES, INC. | 2001-01-23 | — | — | US | disclosed |
| US-6166244-A | Oxygen, sulfur and nitrogen substituted cyclohexene and cyclohexane derivatives having retinoid-like biological activity | ALLERGAN SALES, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000068191-A1 | OXYGEN, SULFUR AND NITROGEN SUBSTITUTED CYCLOHEXENE AND CYCLOHEXANE DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000068190-A2 | 1-ALKOXY AND 1-ACYLOXY SUBSTITUTED CYCLOHEX-1-ENE COMPOUNDS AND SULFUR AND 1-ALKOXYCARBONYL ANALOGS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | HDAC4 859/4885HDAC6 1725/4885ALDH1A1 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.